A Safety Study of SEA-BCMA in Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT03582033. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-BCMA should be given for treatment and how often. It will also find out how safe the treatment is and how well it works. In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Part D, participants will get SEA-BCMA, dexamethasone, and pomalidomide. Dexamethasone and pomalidomide are both drugs that can be used to treat multiple myeloma. These parts of the study will find out whether these drugs are safe when used together.
Study identification
- NCT ID
- NCT03582033
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 83 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 1, 2018 (Actual)
- Primary completion
- Nov 9, 2023 (Actual)
- Completion
- Nov 9, 2023 (Actual)
- Last update posted
- Dec 24, 2024
2018 – 2023
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University School of Medicine | Palo Alto | California | 94304 | — |
| Rocky Mountain Cancer Centers - Aurora | Aurora | Colorado | 80012 | — |
| University of Miami | Miami | Florida | 33136 | — |
| Holden Comprehensive Cancer Center / University of Iowa | Iowa City | Iowa | 52242 | — |
| University of Kansas Cancer Center | Westwood | Kansas | 66205 | — |
| Washington University in St Louis | St Louis | Missouri | 63110 | — |
| Weill Cornell Medicine | New York | New York | 10065 | — |
| James P. Wilmot Cancer Center / University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Texas Oncology - Austin Midtown | Austin | Texas | 78705 | — |
| Texas Oncology - Northeast Texas | Tyler | Texas | 75702 | — |
| Virginia Cancer Specialists, PC | Fairfax | Virginia | 22031 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03582033, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 24, 2024 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03582033 live on ClinicalTrials.gov.